Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?
M.C. Nguyen, Yu Liang Lim, Antony Walton, Jeffrey Lefkovits, Giancarlo Agnelli, Shaun G. Goodman, Andrzej Budaj, Dietrich C. Gulba, Jeanna Allegrone, David Brieger (2007). Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?. , 28(14), DOI: https://doi.org/10.1093/eurheartj/ehm186.
Article323 days agoLow-molecular-weight heparin alone and with IIb/IIIa inhibitors in patients with renal failure and non-ST elevation acute coronary syndromes: Insights from the global registry of acute coronary events
Jean‐Philippe Collet, Giancarlo Agnelli, Frans J. ban de Werf, David Brieger, Enrique Gurfinkel, José López-Sendón, Neelam Gowda, Gilles Montalescot (2003). Low-molecular-weight heparin alone and with IIb/IIIa inhibitors in patients with renal failure and non-ST elevation acute coronary syndromes: Insights from the global registry of acute coronary events. , 41(6), DOI: https://doi.org/10.1016/s0735-1097(03)82020-x.
Article323 days agoCombination therapy with low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE)
Giancarlo Agnelli, C. P. Cannon, Frans Van de Werf, Álvaro Avezum, Gilles Montalescot, Wolfgang Lankes, BM Kennelly, Tomasz Mazurek, Rachel Kasper, David Brieger (2003). Combination therapy with low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). , 1, DOI: https://doi.org/10.1111/j.1538-7836.2003.tb04648.x.
Article323 days agoSafety of the combination of low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors: observations from the global registry of acute coronary events (GRACE)
CP Cannon, David Brieger, Frans Van de Werf, A Avezum, A Lankes, BM Kennelly, Giancarlo Agnelli, Tomasz Mazurek, Rachel Kasper, Gilles Montalescot (2001). Safety of the combination of low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors: observations from the global registry of acute coronary events (GRACE). , 22
Article323 days agoSafety of the combination of low-molecular weight heparin and glycoprotein IIb/IIIa inhibitors: observations from the GLobal Registry of Acute Coronary Events (GRACE)
CP Cannon, David Brieger, Frans Van de Werf, A Avezum, Gilles Montalescot, Wolfgang Lankes, BM Kennelly, Giancarlo Agnelli, Tomasz Mazurek, Rachel Kasper (2001). Safety of the combination of low-molecular weight heparin and glycoprotein IIb/IIIa inhibitors: observations from the GLobal Registry of Acute Coronary Events (GRACE). , 86
Article323 days ago